Drugs · acquisition-cost intelligence
AMLODIPINE BESYLATE 10 mg
amlodipine besylate· ingredient amlodipineDihydropyridine derivatives· AMLODIPINE BESYLATE 10 mg/1; AMLODIPINE BESYLATE 2.5 mg/1; AMLODIPINE BESYLATE 5 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.01136
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 10 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other amlodipine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| AMLODIPINE BESYLATE 10 mg | $0.01545 | +$0.00410 |
| Lotrel | $0.11766 | +$0.10630 |
| Amlodipine and Benazepril Hydrochloride | $0.14444 | +$0.13310 |
| Amlodipine and Olmesartan Medoxomil | $0.29530 | +$0.28390 |
| Exforge | $0.48831 | +$0.47700 |
| OLMESARTAN MEDOXOMIL, AMLODIPINE and HYDROCHLOROTHIAZIDE | $1.23 | +$1.22 |
| Caduet | $1.41 | +$1.40 |
| telmisartan and amlodipine | $2.85 | +$2.83 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 1
Prior auth 0% · Step therapy 0% · Quantity limit 1% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.